2. Academic Validation
  3. Anti-bacterial and anti-viral nanchangmycin displays anti-myeloma activity by targeting Otub1 and c-Maf

Anti-bacterial and anti-viral nanchangmycin displays anti-myeloma activity by targeting Otub1 and c-Maf

  • Cell Death Dis. 2020 Sep 30;11(9):818. doi: 10.1038/s41419-020-03017-4.
Yujia Xu  # 1 2,  Tong Sun  # 2 3,  Kun Zeng 2,  Min Xu 4,  Jinhao Chen 4,  Xiaofeng Xu 5,  Zubin Zhang 2,  Biyin Cao 2,  Xiaowen Tang 6,  Depei Wu 6,  Yan Kong 3,  Yuanying Zeng 7,  Xinliang Mao 8 9
Affiliations

Affiliations

  • 1 Guangdong Institute of Cardiovascular Diseases, Guangdong Key Laboratory of Vascular Diseases, the Second Affiliated Hospital; Guangdong Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511436, P. R. China.
  • 2 Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, 215123, P. R. China.
  • 3 Department of Neurology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215100, P. R. China.
  • 4 Department of Hematology, Zhangjiagang Hospital of Soochow University, Zhangjiagang, 215620, China.
  • 5 Department of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215100, P. R. China.
  • 6 Department of Urology, Nanjing Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, 210002, P. R. China.
  • 7 Department of Oncology, Suzhou Municipal Hospital, Suzhou, Jiangsu, 215100, P. R. China. zengyuanying@163.com.
  • 8 Guangdong Institute of Cardiovascular Diseases, Guangdong Key Laboratory of Vascular Diseases, the Second Affiliated Hospital; Guangdong Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511436, P. R. China. xinliangmao@gzhmu.edu.cn.
  • 9 Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, 215123, P. R. China. xinliangmao@gzhmu.edu.cn.
  • # Contributed equally.
PMID: 32999280 DOI: 10.1038/s41419-020-03017-4
Abstract

As a deubiqutinase OTUB1 stabilizes and promotes the oncogenic activity of the transcription factor c-Maf in multiple myeloma (MM), a malignancy of plasma cells. In the screen for bioactive inhibitors of the OTUB1/c-Maf axis for MM treatment, nanchangmycin (Nam), a polyketide Antibiotic, was identified to suppress c-Maf activity in the presence of OTUB1. By suppressing OTUB1, Nam induces c-Maf polyubiquitination and subsequent degradation in proteasomes but does not alter its mRNA level. Consistently, Nam downregulates the expression of CCND2, ARK5, and ITGB7, the downstream genes regulated by c-Maf, and promotes MM cell Apoptosis as evidenced by PARP and Caspase-3 cleavage, as well as Annexin V staining. In line with the hypothesis, overexpression of OTUB1 partly rescues Nam-induced MM cell Apoptosis, and interestingly, when OTUB1 is knocked down, Nam-decreased MM cell survival is also partly ablated, suggesting OTUB1 is essential for Nam anti-MM activity. Nam also displays potent anti-MM activity synergistically with Doxorubicin or lenalidomide. In the in vivo assays, Nam almost completely suppresses the growth of MM xenografts in nude mice at low dosages but it shows no toxicity. Given its safety and efficacy, Nam has a potential for MM treatment by targeting the OTUB1/c-Maf axis.

Figures
Products